GenScript Biotech’s subsidiary GenScript Biotech Singapore has signed an agreement with UAE’s G42 Healthcare for exploring new solutions to fight against Covid-19.
As part of the deal, the GenScript cPass SARS-CoV-2 neutralisation antibody detection kits will be distributed across 24 locations in the MENA region to assess the effectiveness of vaccines.
This kit detects neutralising antibodies in individuals without using the live SARS-CoV-2 virus.
The conventional method for the measurement of neutralising antibodies in patient samples needs the use of live cells and a high biosafety level environment (BSL3). The results are obtained after several days.
The new cPass antibody detection kit uses pure proteins and can be performed in most standard laboratories in less than an hour.
GenScript noted that the neutralising antibodies represent the first line of defence against the infection by blocking the virus from binding to the host cells, as a result, inhibiting viral propagation.
The cPass kit is said to be the only US FDA Emergency Use Authorized (EUA) serology test for neutralising antibodies from recent and prior infections of the virus.
G42 Healthcare CEO Ashish Koshy said: “Our mission is to provide the definitive, comprehensive and most technologically advanced healthcare solutions in the GCC region.
“Our collaboration with GenScript comes at a time when countries have successfully rolled out national vaccination programs and laboratories can now benefit from rapid detection of the antibodies, thus supporting the healthcare ecosystem.
“Our commitment is to uphold patient health and reinforce our credentials as a trail-blazer in healthcare transformation for the good of all humanity.”